Cerus blood
WebNov 30, 2024 · Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation November 30, 2024 08:30 AM Eastern Standard Time CONCORD, Calif.-- ( BUSINESS WIRE )--Cerus... WebCerus has developed a technology to crosslink nucleic acids and inactivate infectious pathogens and leukocytes in red blood cell components using a proprietary chemical, S-303, and a quencher glutathione (GSH), in a pH …
Cerus blood
Did you know?
WebApr 9, 2024 · Cerus had a negative net margin of 26.40% and a negative return on equity of 57.08%. On average, research analysts expect that Cerus Co. will post -0.18 earnings per share for the current fiscal year. WebCerus. Mar 2024 - Present2 months. New York, United States. Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products ...
WebINTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. Overview (Annual Report) 2024 Annual Report (707 KB) Overview (Safe-Harbor) View Cerus' Safe-Harbor Statement (14 KB) Corporate Presentation (Feb 2024) Investor Relations Contact Phone: 925-288-6137 E-mail: [email protected] Web2 days ago · Cerus Corporation Celebrates World Blood Donor Day 2024. CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. For over 15 years, World Blood Donor Day has helped served as an ...
WebAbout Cerus. Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital … Annual Meeting - Homepage - Cerus Corporate Site Products - Homepage - Cerus Corporate Site Leadership - Homepage - Cerus Corporate Site Press Releases - Homepage - Cerus Corporate Site About Cerus - Homepage - Cerus Corporate Site Learn - Homepage - Cerus Corporate Site Careers - Homepage - Cerus Corporate Site Mission and Values - Homepage - Cerus Corporate Site Cerus’ new corporate brand is inspired by its unwavering commitment to blood … WebMay 17, 2024 · CONCORD, Calif.-- (BUSINESS WIRE)--. Cerus Corporation (Nasdaq:CERS) today announced its contract with Canadian Blood Services for the …
WebNov 1, 2024 · CONCORD, Calif.-- (BUSINESS WIRE)-- Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for …
WebGlobal Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Notice Legal Privacy Policy Copyright (c) 2024 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. severin autogroup hörbyWebMay 3, 2024 · CONCORD, Calif.-- (BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. This new contract replaces the current one with Fresenius Kabi that was set to expire in July 2025. severin bc 7035 check24WebFeb 24, 2024 · CONCORD, Calif.-- ( BUSINESS WIRE )--Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with... severina raine reading orderWebINTERCEPT BLOOD SYSTEM. Effective in reducing the risk of transfusion-transmitted infections (TTI), 12 pathogen reduction for platelet components provides a solution … severin bc 7035 idealoWebFeb 24, 2024 · CONCORD, Calif.-- ( BUSINESS WIRE )-- Cerus Corporation (Nasdaq: CERS) and Shandong Zhongbaokang Medical Implements Co. Ltd. (ZBK) today announced that they are forming a joint venture (JV) with the intent to develop, obtain regulatory approval for, manufacture and commercialize the INTERCEPT Blood System … severin borer ag büsserachWebApr 9, 2024 · On average, research analysts expect that Cerus Co. will post -0.18 earnings per share for the current fiscal year. About Cerus . Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. the trans canada highwayWeb1 Cerus Corporation, Concord, California. PMID: 31930533 ... and glutathione (GSH) is designed to inactivate blood-borne pathogens and leukocytes in red blood cell concentrates (PR-RBCC). Inactivation is attained after amustaline intercalates and forms covalent nucleic acid adducts preventing replication, transcription, and translation. After ... severin blu ray forum